Ke Fu

1.8k total citations · 1 hit paper
41 papers, 1.3k citations indexed

About

Ke Fu is a scholar working on Molecular Biology, Epidemiology and Complementary and alternative medicine. According to data from OpenAlex, Ke Fu has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Epidemiology and 12 papers in Complementary and alternative medicine. Recurrent topics in Ke Fu's work include Liver Disease Diagnosis and Treatment (13 papers), Liver physiology and pathology (7 papers) and Traditional Chinese Medicine Analysis (6 papers). Ke Fu is often cited by papers focused on Liver Disease Diagnosis and Treatment (13 papers), Liver physiology and pathology (7 papers) and Traditional Chinese Medicine Analysis (6 papers). Ke Fu collaborates with scholars based in China and Thailand. Ke Fu's co-authors include Cheng Ma, Lihong Gong, Honglin Zhou, Yafang Zhang, Yunxia Li, Yunxia Li, Yuqin Guo, Cheng Wang, Cheng Wang and Cheng Peng and has published in prestigious journals such as Frontiers in Immunology, Molecules and Nutrients.

In The Last Decade

Ke Fu

39 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Macrophage Polarization and Its Role in Liver Disease

2021 397 citations Cheng Ma, Lihong Gong et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ke Fu China	18	528	274	217	167	159	41	1.3k
Cheng Ma China	17	512 1.0×	320 1.2×	215 1.0×	133 0.8×	187 1.2×	25	1.1k
Lihong Gong China	23	728 1.4×	438 1.6×	277 1.3×	258 1.5×	227 1.4×	46	1.6k
Yong Jin China	23	720 1.4×	251 0.9×	124 0.6×	128 0.8×	136 0.9×	56	1.4k
Xin Han China	20	460 0.9×	258 0.9×	98 0.5×	134 0.8×	130 0.8×	59	1.1k
Xingtao Zhao China	17	512 1.0×	195 0.7×	107 0.5×	147 0.9×	67 0.4×	33	1.1k
Shuang Jiang China	27	972 1.8×	228 0.8×	133 0.6×	349 2.1×	101 0.6×	65	1.7k
Moustafa Fathy Egypt	24	557 1.1×	195 0.7×	123 0.6×	229 1.4×	125 0.8×	70	1.4k
Jinhao Zeng China	22	663 1.3×	236 0.9×	121 0.6×	232 1.4×	51 0.3×	114	1.6k
Wenwen Wang China	17	329 0.6×	214 0.8×	100 0.5×	143 0.9×	128 0.8×	32	932
Chunfeng Lu China	26	646 1.2×	592 2.2×	110 0.5×	201 1.2×	343 2.2×	47	1.5k

Countries citing papers authored by Ke Fu

Since Specialization

Citations

This map shows the geographic impact of Ke Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Fu more than expected).

Fields of papers citing papers by Ke Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ke Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Fu. The network helps show where Ke Fu may publish in the future.

Co-authorship network of co-authors of Ke Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Ke Fu. A scholar is included among the top collaborators of Ke Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ke Fu. Ke Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Chaoyang, et al.. (2025). Macrophage-endothelial cell crosstalk drives atherosclerotic plaque formation and progression. European Journal of Pharmacology. 1003. 177879–177879.

Fu, Ke, Yiting Chen, Yijing Wang, et al.. (2024). Multi-omics reveal the regulation mechanism in response to freezing tolerance in Dendrobium catenatum. Plant Growth Regulation. 104(1). 535–547.

Wang, Cheng, Yanzhi Li, Lihong Gong, et al.. (2024). Phillygenin Inhibits TGF-β1-induced Hepatic Stellate Cell Activation and Inflammation: Regulation of the Bax/Bcl-2 and Wnt/β-catenin Pathways. Inflammation. 47(4). 1403–1422. 3 indexed citations

Xue, Xinyan, Jing Wang, Ke Fu, et al.. (2023). The role of miR-155 on liver diseases by modulating immunity, inflammation and tumorigenesis. International Immunopharmacology. 116. 109775–109775. 12 indexed citations

Gong, Lihong, Honglin Zhou, Cheng Wang, et al.. (2023). CD44‐Targeting Drug Delivery System of Exosomes Loading Forsythiaside A Combats Liver Fibrosis via Regulating NLRP3‐Mediated Pyroptosis. Advanced Healthcare Materials. 12(11). e2202228–e2202228. 57 indexed citations

Fu, Ke, Shu Dai, Yanzhi Li, et al.. (2023). The protective effect of forsythiaside A on 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced cholestatic liver injury in mice: Based on targeted metabolomics and molecular biology technology. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1869(8). 166822–166822. 5 indexed citations

Ma, Cheng, Cheng Wang, Yafang Zhang, et al.. (2023). Phillygenin inhibited M1 macrophage polarization and reduced hepatic stellate cell activation by inhibiting macrophage exosomal miR-125b-5p. Biomedicine & Pharmacotherapy. 159. 114264–114264. 37 indexed citations

Yao, Chenhao, Cheng Wang, Ke Fu, et al.. (2023). Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies. Biomedicine & Pharmacotherapy. 167. 115464–115464. 53 indexed citations

Dai, Shu, Rui Wu, Ke Fu, et al.. (2023). Exploring the effect and mechanism of cucurbitacin B on cholestatic liver injury based on network pharmacology and experimental verification. Journal of Ethnopharmacology. 322. 117584–117584. 13 indexed citations

10.

Wang, Cheng, Yanfang Liu, Lihong Gong, et al.. (2023). Phillygenin Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis: Suppression of Inflammation and Wnt/β-Catenin Signaling Pathway. Inflammation. 46(4). 1543–1560. 14 indexed citations

11.

Liang, Yan, Rong Zeng, Ran Li, et al.. (2023). Qualitative and quantitative analyses of chemical constituents in vitro and in vivo and systematic evaluation of the pharmacological effects of Tibetan medicine Zhixue Zhentong capsules. Frontiers in Pharmacology. 14. 1204947–1204947. 3 indexed citations

12.

Ma, Cheng, Linfeng He, Li Liao, et al.. (2022). Tetramethylpyrazine Protects Endothelial Injury and Antithrombosis via Antioxidant and Antiapoptosis in HUVECs and Zebrafish. Oxidative Medicine and Cellular Longevity. 2022(1). 2232365–2232365. 16 indexed citations

13.

Fu, Ke, Honglin Zhou, Cheng Wang, et al.. (2022). A review: Pharmacology and pharmacokinetics of Schisandrin A. Phytotherapy Research. 36(6). 2375–2393. 30 indexed citations

14.

Wang, Cheng, Cheng Ma, Ke Fu, et al.. (2022). Hepatoprotective effect of phillygenin on carbon tetrachloride-induced liver fibrosis and its effects on short chain fatty acid and bile acid metabolism. Journal of Ethnopharmacology. 296. 115478–115478. 26 indexed citations

15.

Dai, Shu, Cheng Wang, Xingtao Zhao, et al.. (2022). Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics. Pharmacological Research. 187. 106587–106587. 64 indexed citations

16.

Fu, Ke, Cheng Ma, Cheng Wang, et al.. (2022). Forsythiaside A alleviated carbon tetrachloride-induced liver fibrosis by modulating gut microbiota composition to increase short-chain fatty acids and restoring bile acids metabolism disorder. Biomedicine & Pharmacotherapy. 151. 113185–113185. 40 indexed citations

17.

Fu, Ke, Cheng Wang, Cheng Ma, Honglin Zhou, & Yunxia Li. (2021). The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Frontiers in Pharmacology. 12. 771459–771459. 29 indexed citations

18.

Li, Xiaoli, You Zhou, Min Xu, et al.. (2020). Data mining on varieties, therapeutic uses and medicinal characteristics of Traditional Chinese Medicine preparations for treating hair loss. Tropical Journal of Pharmaceutical Research. 19(11). 2461–2475. 1 indexed citations

19.

Fu, Ke, Min Xu, You Zhou, et al.. (2020). The Status quo and way forwards on the development of Tibetan medicine and the pharmacological research of tibetan materia Medica. Pharmacological Research. 155. 104688–104688. 46 indexed citations

20.

Li, Chunhua, et al.. (2019). Increased expression of thymic stromal lymphopoietin receptor in a rat model of middle cerebral artery occlusion. Neuroreport. 30(3). 182–187. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact